IVF Slump: Monash IVF's 4.7% Cycle Drop Signals Healthcare Access Crisis

For healthcare leaders, Monash IVF's announcement is a sentinel event: a 4.7% decline in ART cycles means thousands of hopeful parents are stepping away from treatment. Whether driven by out-of-pocket costs, economic anxiety, or lingering trust issues from the 2025 embryo scandal, the downturn threatens the viability of a sector that serves as a cornerstone of reproductive health. This moment demands a hard look at how we fund and deliver fertility services to ensure equitable access.

Monash IVF, Australia's second-largest provider of assisted reproductive technology (ART) with an approximately 20% market share, has issued a stark profit warning that reverberates across the healthcare sector. The company now expects underlying net profit for the 2025/26 financial year to fall between $17 million and $18 million, a notable downgrade from its previous guidance of around $20 million. The catalyst is a clear softening in domestic demand: Medicare data cited by Monash shows that stimulated cycle volumes—the core metric for IVF treatment—fell 4.7% in the three months to April 2026 compared with the same period a year earlier. Management further warned that the adverse conditions have persisted through May and June, painting a grim near-term picture for the industry.

“

The company now expects underlying net profit for the 2025/26 financial year to fall between $17 million and $18 million, a notable downgrade from its previous guidance of around $20 million.

This development is not an isolated corporate event but rather a signal of broader headwinds in Australia's fertility services market. The two dominant players, Virtus Health (ASX:VRT) with roughly 40% market share and Monash IVF, together account for the majority of ART cycles performed in the country. A sustained decline in stimulated cycles, therefore, implies systemic softness that likely affects the entire sector, even if other firms have yet to report. Potential drivers include the cost-of-living crisis, elevated interest rates, and housing affordability pressures that disproportionately hit the younger demographics most likely to seek fertility treatment. Additionally, shifting social patterns—such as delayed childbearing or increased uptake of alternative family-building methods—may be influencing demand. Whatever the cause, the Medicare data offers hard evidence that fewer Australians are embarking on IVF journeys, with implications for clinic revenues, employment, and investment in reproductive technology.

The earnings downgrade also casts a shadow over Monash IVF's corporate narrative. The company is in the midst of a cost-cutting program, which suggests management is bracing for a potentially extended downturn. However, its international operations offer a silver lining, with second-half volumes expected to exceed last year's levels—a diversification benefit that pure-play domestic competitors may lack. The rejection of an unsolicited 90-cents-per-share indicative offer from WHSP Holdings and Genesis Capital in April, deemed by the board as a substantial discount, highlights ongoing private equity interest in the space. That interest, originally sparked amid the fallout from a high-profile embryo implant scandal in November 2025—where human error and IT limitations led to a patient receiving her own embryo instead of her partner's—underscores the volatility of the IVF business, where clinical trust is paramount. The scandal may have caused reputational damage that, when combined with macroeconomic pressures, accelerated a pullback in consumer confidence.